Research programme: amyloid precursor protein secretase inhibitors - Merck & Co

Drug Profile

Research programme: amyloid precursor protein secretase inhibitors - Merck & Co

Alternative Names: BACE programme - Merck & Co; SCH 697466; SCH 723909; SCH 741216; SCH 747123; SCH-1375975; SCH-745966; β-secretase-1 inhibitors - Merck & Co; γ-secretase inhibitors - Merck & Co

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co
  • Class Amides; Hydantoins; Small molecules; Urea compounds
  • Mechanism of Action Amyloid precursor protein secretase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)
  • 13 Nov 2010 Pharmacodynamics data from animal studies in Alzheimer's disease presented at the 40th Annual Meeting of the Society for Neuroscience (SFN-2010)
  • 20 Aug 2009 Pharmacodynamics data from in vitro and preclinical studies in Alzheimer's disease presented at the 238th American Chemical Society National Meeting (238th-ACS-2009) ,,,,,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top